Cash Flow Statement continued Reconciliation of Net Cash Flow to Movement in Net Debt 2010 2009 2008 $ million $ million $ million Change in cash net of overdrafts in the year 15 44 18 Settlement of currency swaps 3 12 5 Net change in borrowings 420 354 31 Change in net debt fromnet cash flow 438 410 18 Facilityfee paid -- 2 Exchange adjustment 13 21 6 Change in net debt in the year 451 389 22 Opening net debt 943 1,332 1,310 Closing net debt 492 943 1,332 Cash and Cash Equivalents For the purposes of the Group Cash Flow Statement cash and cash equivalents at 31 December comprise cash at bank and in hand net of bank overdrafts.
2010 2009 2008 $ million $ million $ million Cash at bank and in hand 207 192 145 Bank overdrafts 12 18 23 Cash and cash equivalents 195 174 122 28.
CurrencyTranslation The exchange rates used for the translation of currencies into US Dollars that have the most significant impact on the Group results were: Averagerates 2010 2009 2008 Sterling 1.54 1.56 1.84 Euro 1.32 1.39 1.46 SwissFranc 0.96 0.92 0.92 Year-end rates 2010 2009 2008 Sterling 1.57 1.61 1.44 Euro 1.34 1.43 1.39 SwissFranc 1.07 0.97 0.94 29.
Acquisitions Year ended 31 December2010 In the year ended 31 December 2010there were no acquisitions.
Year ended 31 December2009 Plus Orthopedics Holdings AG In January 2009, the Group reached an agreement with the vendors of Plus to reduce the total original purchase price by CHF159m.
As part of the agreement the Group dropped all its claims and released the vendors from substantially all of the remaining warranties under the originalpurchase agreement as well as resolving the contractual price adjustments.
2010Annual Report 119 InvestorInformation CompanyAccounts GroupAccounts  CorporateGovernance BusinessReview, Descriptionof theGroup Report Statement  29.
Acquisitions continued Nucryst Pharmaceuticals, Corp. On 22 December 2009, the Group acquired substantially all of the assets and liabilities of Nucryst Pharmaceuticals, Corp, which manufactures and licences exclusively to the Group our range of ACTICOAT products, using its nanocrystalline silver technology, SILCRYST.
Under the agreement the Group acquired the manufacturing assets fromNucrysts operations in Canada and intellectual property rights relating to the nanocrystalline silver technology used in the manufacture of ACTICOAT product range.
Nucryst has manufactured ACTICOAT products forSmith&Nephew since the Groups acquisition of the product right in 2001.
Pre-acquisition Fair value Fair value to Group carryingamounts adjustments reportedin 2009 $ million $ million $ million Property, plant and equipment 10 4 6 Intangible assets acquisition intangibles - 12 12 Inventories 4 - 4 Trade and other payables 1 - 1 Deferred taxation - 1 1 Net assets 13 9 22 Goodwillon acquisition 3 Cost of acquisition 25 Discharged by: Cash 25 Management believes that goodwill represents the value of the workforce and synergies that are expected to arise from the combined group.
As the Group was the only material customer of Nucryst Pharmaceuticals, Corp. no contribution to revenue was achieved in 2009.
The post-acquisition contribution to attributable profitfor2009was immaterial.
Year ended 31 December2008 The aggregate impact of acquisitions that occurred during 2008 is set out below.
The acquisitions primarily relate to minority interest and distributor buyouts, as a result of the Plus acquisition concluded in 2007.
There is no material difference between the fair value and book value of the net assets acquired.
$ million Deferred taxation 1 Intangible assets 1 Assets acquired 2 Goodwill i 2 Cost of acquisition - Dischargedby Cash 2 Deferred consideration i 2 - i Relating tothe  previouslyonthe basisofcontingent consideration.
In 2008, deferred consideration of $14min respect of the previous years acquisitions was paid.
